A5011413583- Renal Transplantation Outcomes and Treatments
- Cytomegalovirus and herpesvirus research
- Polyomavirus and related diseases
- Pregnancy and Medication Impact
- Alzheimer's disease research and treatments
- Palliative Care and End-of-Life Issues
- Pharmacological Effects and Toxicity Studies
- Drug Transport and Resistance Mechanisms
- Management of metastatic bone disease
- Oral microbiology and periodontitis research
- Brain Metastases and Treatment
- Pharmacogenetics and Drug Metabolism
- Herpesvirus Infections and Treatments
- CAR-T cell therapy research
- HIV/AIDS drug development and treatment
- Neuroinflammation and Neurodegeneration Mechanisms
- Adenosine and Purinergic Signaling
University of Washington
2024-2025
Emulate (United States)
2024
Centre Hospitalier Universitaire de Clermont-Ferrand
2007-2016
Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the transplant setting. No longitudinal cohort studies of CMV real-life setting have been published valganciclovir era. We report findings for French multicentre prospective 346 patients enrolled at initial diagnosis infection (clinical trial registered clinicaltrials.gov: NCT01008540). Patients were monitored detection ≥2 years. Real-time by UL97 and UL54 gene sequencing antiviral phenotyping was performed if viral...
Abstract Colocalization of microbial pathogens and the β-amyloid peptide (Aβ) in brain Alzheimer’s disease (AD) patients suggests that infection may play a role sporadic AD. Aβ exhibits antimicrobial activity against numerous pathogens, supporting potential for innate immune response. While mammalian amyloid is associated with disease, many bacteria form fibrils to fortify biofilm protects cells from surrounding environment. In AD hypothesis, aggregates response combat pathogen. We...
Pretransplantation adaptation of the daily dose tacrolimus to CYP3A5 genotype is associated with improved achievement target trough concentration (C0 ), but whether this improvement affects clinical outcomes unknown. In present study, we have evaluated long-term impact initial dosing according genotype: The transplantation 236 kidney transplant recipients included in Tactique study were retrospectively investigated over a period more than 5 years. patients randomly assigned receive at either...
Abstract Background End‐stage renal disease ( ESRD ) is associated with premature aging of the T‐cell system. Nevertheless, clinical significance pre‐transplant ‐related immune senescence unknown. Methods We studied whether risk phenotype IRP ), a typical feature senescence, may affect post‐transplant infectious complications. A total 486 patients were prospectively during first year post transplant. was defined as positive cytomegalovirus serology at least 1 following criteria: CD 4/ 8...
Objectives: Among patients that underwent palliative RT (pRT) at a single institution, we evaluated whether differences exist across race and ethnicity in location of pRT consultation delivery pRT. Methods: This retrospective study included cancer aged 18 years or older who received between 10/2021 10/2022. Logistic regression models were used to examine univariable (UVA) multivariable (MVA) associations consult the inpatient (vs. outpatient) setting. A subset analysis quality metrics for...
Any biochemical reaction underlying drug metabolism depends on individual gene-drug interactions and groups of genes interacting together. Based a high-throughput genetic approach, we sought to identify set covariant single-nucleotide polymorphisms predictive interindividual tacrolimus (Tac) dose requirement variability. Tac blood concentrations (Tac C0 ) 229 kidney transplant recipients were repeatedly monitored after transplantation over 3 mo. Given the high dimension genomic data in...
Short-term intensified dosing using enteric-coated mycophenolate sodium (EC-MPS) reduces rejection after kidney transplantation without compromising safety and may facilitate steroid avoidance. In a 6-month, multicentre open-label trial, 222 de novo transplant recipients at low-immunological risk were randomized to avoidance or maintenance steroids with interleukin (IL)-2 receptor antibody (IL-2RA) induction, EC-MPS (2160 mg/day Week 6, 1440 thereafter) cyclosporine. The primary end point;...
Abstract Objective. Chimeric antigen (CAR) T-cell therapies for solid tumors are challenging to develop due the lack of human relevant models that adequately capture mechanisms CAR recruitment-a critical yet often overlooked rate-limiting step. The current study aimed a novel system investigating both recruitment and killing capacity T cells in Organ-Chips. Methods. Chip-S1™ Stretchable Chips (Emulate) were seeded with HER2+ non-small cell lung cancer line (NSCLC) top channel microvascular...